As showdown with activist nears, Illumina’s CEO defends the company’s $7.1B purchase of Grail
Two years after Illumina bought the cancer testing company Grail, the DNA sequencing giant remains beleaguered by antitrust issues and is weeks away from the results of a proxy fight that will determine its future.
Despite the pressures on Illumina and calls for his job by activist investor Carl Icahn, CEO Francis deSouza in an interview with Endpoints News defended the $7.1 billion acquisition in 2021 as critical to Illumina’s growth, and the quickest path for scaling Grail’s early-detection tests to reach more people.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.